Sean P Korpela1, Trista K Hinz1, Ayman Oweida2, Jihye Kim3, Jacob Calhoun1, Robert Ferris4, Raphael A Nemenoff3, Sana D Karam5, Eric T Clambey6, Lynn E Heasley7,8. 1. Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical Campus, 12801 E. 17th Ave, Aurora, CO, 80045, USA. 2. Department of Nuclear Medicine and Radiobiology, Universite de Sherbrooke, Sherbrooke, Québec, Canada. 3. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 4. Departments of Otolaryngology and Immunology, University of Pittsburgh, Pittsburgh, PA, USA. 5. Department of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 6. Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 7. Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical Campus, 12801 E. 17th Ave, Aurora, CO, 80045, USA. lynn.Heasley@cuanschutz.edu. 8. Eastern Colorado VA Healthcare System, Rocky Mountain Regional VA Medical Center, Aurora, CO, USA. lynn.Heasley@cuanschutz.edu.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the therapeutic antibody, cetuximab, in the management of this cancer. The degree of response to EGFR inhibitors measured by tumor shrinkage varies widely among HNSCC patients, and the biological mechanisms that underlie therapeutic heterogeneity amongst HNSCC patients remain ill-defined. METHODS: EGFR-dependent human and murine HNSCC cell lines were treated with the EGFR/ERBB inhibitors, gefitinib and AZD8931, and submitted to RNAseq, GSEA, and qRT-PCR. Conditioned media was analyzed by ELISA and Luminex assays. Murine HNSCC tumors were stained for T cell markers by immunofluorescence. Primary HSNCC patient specimens treated with single agent cetuximab were stained with Vectra multispectral immunofluorescence. RESULTS: The transcriptional reprogramming response to EGFR/ERBB-specific TKIs was measured in a panel of EGFR-dependent human HNSCC cell lines and interferon (IFN) α and γ responses identified as top-ranked TKI-induced pathways. Despite similar drug sensitivity, responses among 7 cell lines varied quantitatively and qualitatively, especially regarding the induced chemokine and cytokine profiles. Of note, the anti-tumorigenic chemokine, CXCL10, and the pro-tumorigenic factor, IL6, exhibited wide-ranging and non-overlapping induction. Similarly, AZD8931 exerted potent growth inhibition, IFNα/IFNγ pathway activation, and CXCL10 induction in murine B4B8 HNSCC cells. AZD8931 treatment of immune-competent mice bearing orthotopic B4B8 tumors increased CD8 + T cell content and the therapeutic response was abrogated in nu/nu mice relative to BALB/c mice. Finally, Vectra 3.0 analysis of HNSCC patient tumors prior to and after 3-4 weeks of single agent cetuximab treatment revealed increased CD8 + T cell content in specimens from patients exhibiting a therapeutic response relative to non-responders. CONCLUSIONS: The findings reveal heterogeneous, tumor cell-intrinsic, EGFR/ERBB inhibitor-induced IFN pathway activation in HNSCC and suggest that individual tumor responses to oncogene-targeted agents are a sum of direct growth inhibitory effects and variably-induced participation of host immune cells.
BACKGROUND:Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the therapeutic antibody, cetuximab, in the management of this cancer. The degree of response to EGFR inhibitors measured by tumor shrinkage varies widely among HNSCC patients, and the biological mechanisms that underlie therapeutic heterogeneity amongst HNSCC patients remain ill-defined. METHODS:EGFR-dependent human and murine HNSCC cell lines were treated with the EGFR/ERBB inhibitors, gefitinib and AZD8931, and submitted to RNAseq, GSEA, and qRT-PCR. Conditioned media was analyzed by ELISA and Luminex assays. Murine HNSCCtumors were stained for T cell markers by immunofluorescence. Primary HSNCC patient specimens treated with single agent cetuximab were stained with Vectra multispectral immunofluorescence. RESULTS: The transcriptional reprogramming response to EGFR/ERBB-specific TKIs was measured in a panel of EGFR-dependent human HNSCC cell lines and interferon (IFN) α and γ responses identified as top-ranked TKI-induced pathways. Despite similar drug sensitivity, responses among 7 cell lines varied quantitatively and qualitatively, especially regarding the induced chemokine and cytokine profiles. Of note, the anti-tumorigenic chemokine, CXCL10, and the pro-tumorigenic factor, IL6, exhibited wide-ranging and non-overlapping induction. Similarly, AZD8931 exerted potent growth inhibition, IFNα/IFNγ pathway activation, and CXCL10 induction in murineB4B8 HNSCC cells. AZD8931 treatment of immune-competent mice bearing orthotopic B4B8tumors increased CD8 + T cell content and the therapeutic response was abrogated in nu/nu mice relative to BALB/c mice. Finally, Vectra 3.0 analysis of HNSCC patienttumors prior to and after 3-4 weeks of single agent cetuximab treatment revealed increased CD8 + T cell content in specimens from patients exhibiting a therapeutic response relative to non-responders. CONCLUSIONS: The findings reveal heterogeneous, tumor cell-intrinsic, EGFR/ERBB inhibitor-induced IFN pathway activation in HNSCC and suggest that individual tumor responses to oncogene-targeted agents are a sum of direct growth inhibitory effects and variably-induced participation of host immune cells.
Authors: Hyun-Bae Jie; Raghvendra M Srivastava; Athanassios Argiris; Julie E Bauman; Lawrence P Kane; Robert L Ferris Journal: Cancer Immunol Res Date: 2017-04-13 Impact factor: 11.151
Authors: Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Jie Hyun-Bae; Lin Wang; Raja R Seethala; Barton F Branstetter; Soldano Ferrone; Robert L Ferris Journal: Cancer Immunol Res Date: 2015-05-13 Impact factor: 11.151
Authors: Francesca Mascia; Gary Lam; Christopher Keith; Caroline Garber; Seth M Steinberg; Elise Kohn; Stuart H Yuspa Journal: Sci Transl Med Date: 2013-08-21 Impact factor: 17.956
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang Journal: N Engl J Med Date: 2006-02-09 Impact factor: 91.245